These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8993762)

  • 1. The use of transfer factors in chronic fatigue syndrome: prospects and problems.
    Levine PH
    Biotherapy; 1996; 9(1-3):77-9. PubMed ID: 8993762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons from a pilot study of transfer factor in chronic fatigue syndrome.
    De Vinci C; Levine PH; Pizza G; Fudenberg HH; Orens P; Pearson G; Viza D
    Biotherapy; 1996; 9(1-3):87-90. PubMed ID: 8993764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of anti HHV-6 transfer factor for the treatment of two patients with chronic fatigue syndrome (CFS). Two case reports.
    Ablashi DV; Levine PH; De Vinci C; Whitman JE; Pizza G; Viza D
    Biotherapy; 1996; 9(1-3):81-6. PubMed ID: 8993763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral serologies in patients with chronic fatigue and chronic fatigue syndrome.
    Buchwald D; Ashley RL; Pearlman T; Kith P; Komaroff AL
    J Med Virol; 1996 Sep; 50(1):25-30. PubMed ID: 8890037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic fatigue syndrome: evaluation and treatment.
    Craig T; Kakumanu S
    Am Fam Physician; 2002 Mar; 65(6):1083-90. PubMed ID: 11925084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of age on transfer factor treatment of cellular immunodeficiency, chronic fatigue syndrome and/or chronic viral infections.
    Hana I; Vrubel J; Pekarek J; Cech K
    Biotherapy; 1996; 9(1-3):91-5. PubMed ID: 8993765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers.
    Watt T; Oberfoell S; Balise R; Lunn MR; Kar AK; Merrihew L; Bhangoo MS; Montoya JG
    J Med Virol; 2012 Dec; 84(12):1967-74. PubMed ID: 23080504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome.
    Sairenji T; Yamanishi K; Tachibana Y; Bertoni G; Kurata T
    Intervirology; 1995; 38(5):269-73. PubMed ID: 8724857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHV-6 in post-infective fatigue syndrome.
    Cameron B; Flamand L; Juwana H; Middeldorp J; Naing Z; Rawlinson W; Ablashi D; Lloyd A
    J Med Virol; 2010 Oct; 82(10):1684-8. PubMed ID: 20827765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral studies of chronic fatigue syndrome.
    Levy JA
    Clin Infect Dis; 1994 Jan; 18 Suppl 1():S117-20. PubMed ID: 8148437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic fatigue syndrome.
    Kakumanu S; Yeager M; Craig TJ
    J Am Osteopath Assoc; 1999 Oct; 99(10 Su Pt 1):S1-5. PubMed ID: 10624375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.
    Montoya JG; Kogelnik AM; Bhangoo M; Lunn MR; Flamand L; Merrihew LE; Watt T; Kubo JT; Paik J; Desai M
    J Med Virol; 2013 Dec; 85(12):2101-9. PubMed ID: 23959519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue.
    Kogelnik AM; Loomis K; Hoegh-Petersen M; Rosso F; Hischier C; Montoya JG
    J Clin Virol; 2006 Dec; 37 Suppl 1():S33-8. PubMed ID: 17276366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Viral infection and its causative role for chronic fatigue syndrome].
    Okano M
    Nihon Rinsho; 1992 Nov; 50(11):2617-24. PubMed ID: 1337559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Viral infections in chronic fatigue syndrome].
    Sairenji T; Nagata K
    Nihon Rinsho; 2007 Jun; 65(6):991-6. PubMed ID: 17561687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of Epstein-barr Virus and/or cytomegalovirus in patients with chronic fatigue syndrome.
    Lerner AM; Dworkin HJ; Sayyed T; Chang CH; Fitzgerald JT; Beqaj S; Deeter RG; Goldstein J; Gottipolu P; O'Neill W
    In Vivo; 2004; 18(4):417-24. PubMed ID: 15369178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of viral infection in monozygotic twins discordant for chronic fatigue syndrome.
    Koelle DM; Barcy S; Huang ML; Ashley RL; Corey L; Zeh J; Ashton S; Buchwald D
    Clin Infect Dis; 2002 Sep; 35(5):518-25. PubMed ID: 12173124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome.
    Lerner AM; Beqaj SH; Deeter RG; Fitzgerald JT
    In Vivo; 2004; 18(2):101-6. PubMed ID: 15113035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up.
    Lerner AM; Beqaj SH; Deeter RG; Fitzgerald JT
    In Vivo; 2007; 21(5):707-13. PubMed ID: 18019402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The chronic fatigue syndrome. A multifactorial approach and the treatment possibilities].
    Pinardi G; Scarlato G
    Recenti Prog Med; 1990 Dec; 81(12):773-7. PubMed ID: 2075278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.